Cancer Research AACR Membership  Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boukerche, H.
Right arrow Articles by Thomas, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boukerche, H.
Right arrow Articles by Thomas, L.
[Cancer Research 60, 5848-5856, October 15, 2000]
© 2000 American Association for Cancer Research


Tumor Biology

A New Mr 55,000 Surface Protein Implicated in Melanoma Progression: Association with a Metastatic Phenotype1

Habib Boukerche2,3, Patrick Baril2, Eric Tabone, Frédéric Bérard, Kamel Sanhadji, Brigitte Balme, François Wolf, Henri Perrot and Luc Thomas

Institut National de la Santé et de la Recherche Médicale U331, Faculty of Medicine René Laënnec, 69372 Lyon Cedex 08 [H. B., P. B.]; Department of Pathology, Anti-Cancer Center Léon Bérard, 69373 Lyon Cedex 08 [E. T.]; Department of Dermatology, Hôpital de l’Antiquaille, 69321 Lyon Cedex 08 [F. B., B. B., F. W., H. P., L. T.]; and Institut National de la Santé et de la Recherche Médicale U80, Faculty of Medicine René Laënnec, 69372 Lyon Cedex 08 [K. S.], France

Emergence of the invasive phenotype is a key event in the progression of human melanoma from benign proliferative lesions to malignant lesions. Recently we successfully selected in vivo from a poorly metastatic M4Beu. human melanoma cell line two variants (7GP and T1P26) that generate a higher frequency of spontaneous metastases to the lungs into immune-suppressed neonatal rats. Both cell lines showed no significant differences in the integrin profile of the subunits analyzed except for ß3, which was reduced to a background level in metastatic variants. To investigate how these variant sublines of human melanomas manage to sustain growth in the absence of {alpha}vß3, a subtractive immunization approach was used to elicit host antibody response against cell surface proteins expressed on metastatic variants. In this study, a new monoclonal antibody (MoAb), LY1, that is highly specific for the 7GP and T1P26 variants, was isolated. LY1 identifies a membrane protein of Mr 55,000 on melanoma variants with epitopes that were resistant to sugar-cleaving enzymes. Immunostaining cells from variants by LY1 showed that staining is distributed to the cell periphery with high labeling intensity at the cell-to-cell contact points. This MoAb significantly inhibited invasion of metastatic variants through a reconstituted basement membrane (Matrigel) in vitro. Moreover, tumor growth of melanoma variants was dramatically affected in vivo with this MoAb. In vitro studies indicate that the LY1 MoAb does not inhibit chemotactic migration of the metastatic variants, the adhesion of tumor cells to vitronectin, collagen IV, fibronectin, and laminin, or cell proliferation. Expression of this antigen is high in human striated muscle, heart, spleen, brain, and lung and absent in kidney, liver, and pancreas. Using 59 fixed, paraffin-embedded archival tissues of human melanomas and nevi, LY1-reactive cells were not observed in melanocytes, nevi, or radial growth phase primary melanomas. In sharp contrast, LY1 selectively stained melanocytes derived from the vertical growth phase of many primary melanomas and metastatic melanomas. These results provide evidence that the Mr 55,000 protein expressed by selected variants with increased metastatic properties in vivo plays a functionally important role in determining metastasis. This molecule may represent a new metastatic risk marker in human melanoma and may be of biological importance in the identification of fatal metastatic subpopulations that have acquired competence for metastasis production.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Boukerche, Z.-z. Su, C. Prevot, D. Sarkar, and P. B. Fisher
mda-9/Syntenin promotes metastasis in human melanoma cells by activating c-Src
PNAS, October 14, 2008; 105(41): 15914 - 15919.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Boukerche, Z.-z. Su, L. Emdad, D. Sarkar, and P. B. Fisher
mda-9/Syntenin Regulates the Metastatic Phenotype in Human Melanoma Cells by Activating Nuclear Factor-{kappa}B
Cancer Res., February 15, 2007; 67(4): 1812 - 1822.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Boukerche, Z.-z. Su, L. Emdad, P. Baril, B. Balme, L. Thomas, A. Randolph, K. Valerie, D. Sarkar, and P. B. Fisher
mda-9/Syntenin: A Positive Regulator of Melanoma Metastasis
Cancer Res., December 1, 2005; 65(23): 10901 - 10911.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.